Abstract
Bispecific antibodies (BsAbs) are thought to have a promising clinical application and many R&D companies include them in their R&D pipeline. We tried to analyze the technology flows pattern of BsAbs by patent citation network, then identified technological opportunities and risks of different drug targets for R&D companies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
